Trial Profile
An Open-label, Non-randomized, Single-dose, Parallel-group, Safety, Tolerability, and Pharmacokinetic Study of Tucatinib Administered at 300 mg in Fasted, Hepatically-impaired Male and Female Subjects and Fasted Matched-control Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Dec 2022
Price :
$35
*
At a glance
- Drugs Tucatinib (Primary)
- Indications Biliary cancer; Bladder cancer; Breast cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; HER2 positive breast cancer; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Seagen
- 05 Dec 2022 Results of PK and safety of tucatinib in volunteers with hepatic impairment, published in the Clinical Pharmacokinetics
- 10 Apr 2021 Results presented at the 112th Annual Meeting of the American Association for Cancer Research.
- 16 May 2019 Status changed from recruiting to completed.